Evidence map›Paper›PMID 38903497›Full record

ArticleFrontiers in immunology2024

Proliferating macrophages in human tumours show characteristics of monocytes responding to myelopoietic growth factors.

Saem Mul Park, Chun-Jen J Chen, Daniel J Verdon, Marcus P Y Ooi, Anna E S Brooks, Richard C W Martin, Jon A Mathy, Patrick O Emanuel, P Rod Dunbar

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Emerging Biomimetic Drug Delivery Nanoparticles Inspired by Extracellular Vesicles.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Saem Mul ParkSchool of Biological Sciences, The University of Auckland, Auckland, New Zealand.
Chun-Jen J ChenSchool of Biological Sciences, The University of Auckland, Auckland, New Zealand.
Daniel J VerdonSchool of Biological Sciences, The University of Auckland, Auckland, New Zealand.
Marcus P Y OoiSchool of Biological Sciences, The University of Auckland, Auckland, New Zealand.
Anna E S BrooksSchool of Biological Sciences, The University of Auckland, Auckland, New Zealand.
Richard C W MartinDepartment of Surgery, Te Whatu Ora Waitemata, Auckland, New Zealand.
Jon A MathyDepartment of Surgery, Faculty of Medical Health Sciences, The University of Auckland, Auckland, New Zealand.
Patrick O EmanuelDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
P Rod DunbarSchool of Biological Sciences, The University of Auckland, Auckland, New Zealand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Macrophages play essential roles in maintaining tissue homeostasis and immune defence. However, their extensive infiltration into tumours has been linked to adverse outcomes in multiple human cancers. Within the tumour microenvironment (TME), tumour-associated macrophages (TAMs) promote tumour growth and metastasis, making them prime targets for cancer immunotherapy. Recent single-cell analysis suggest that proliferating TAMs accumulate in human cancers, yet their origins and differentiation pathways remain uncertain. Here, we show that a subpopulation of CD163+ TAMs proliferates

Indexed as

Cell ProliferationMonocytesTumor-Associated MacrophagesTumor MicroenvironmentAntigens, CDAntigens, Differentiation, MyelomonocyticBreast NeoplasmsCD163 AntigenCytokinesFemaleHumansMacrophagesNeoplasmsReceptors, Cell SurfaceT-LymphocytesAntigens, CDAntigens, Differentiation, MyelomonocyticCD163 AntigenCytokinesReceptors, Cell Surfaceimmunosuppressionmacrophage proliferationmelanomatumour-associated macrophagestumour microenvironment

Identifiers

PMID38903497
PMCPMC11188303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.